UAB || Division of Human Gene Therapy

Joanne T. Douglas, Ph.D.

Assistant Professor
Division of Human Gene Therapy
Dept. of Pathology

Biomedical Research Building II
901 19th Street South, BMR II - 412
Birmingham, AL 35294-2172

Email: joanne.douglas@ccc.uab.edu
Phone: (205) 975-2897
Fax: (205) 975-8565

Research Interests

In my laboratory, we are developing targeted adenoviral vectors for novel therapeutic approaches to a range of diseases, particularly disorders of the muscle and bone. In addition, we are employing both replication-defective adenoviral vectors and armed replicating adenoviruses in the treatment of cancer, with an emphasis on primary and metastatic breast cancer. On a more basic level, we are using transgenic mouse models to try to elucidate the biological barriers to efficient adenoviral infection of mature skeletal muscle and the airway epithelium.

Select List of Publications

Krasnykh VN, Mikheeva GV, Douglas JT and Curiel DT (1996). Generation of recombinant adenoviral vectors with modified fibers for altering viral tropism. J Virol 70: 6839-6846.
Douglas JT, Rogers BE, Rosenfeld ME, Michael SI, Feng M and Curiel DT (1996). Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotechnol 14: 1574-1578.
Zinn KR, Douglas JT, Smyth C, Liu H-G, Wu Q, Krasnykh VN, Mountz JD, Curiel DT and Mountz JM (1998). Imaging and tissue biodistribution of Tc-99m-labeled adenovirus knob (serotype 5). Gene Ther 5: 798-808.
Reynolds PR, Miller CR, Goldman CK, Doukas J, Sosnowski BA, Rogers BE, Gomez-Navarro J, Pierce GF, Curiel DT and Douglas JT (1998). Targeting adenoviral infection with basic fibroblast growth factor enhances gene delivery to vascular endothelial and smooth muscle cells. Tumor Target 3: 156-168.
Douglas JT, Miller CR, Kim M, Dmitriev I, Mikheeva G, Krasnykh V and Curiel DT (1999). A system for the propagation of adenoviral vectors with genetically modified receptor specificities. Nat Biotechnol 17: 470-475.
Gómez-Navarro J, Curiel DT and Douglas JT (1999). Gene therapy for cancer. Eur J Cancer 35: 867-885.
Krasnykh VN, Douglas JT and van Beusechem VW (2000). Genetic targeting of adenoviral vectors. Mol Ther 1: 391-405.
Tillman BW, Hayes TL, de Gruijl TD, Douglas JT and Curiel DT (2000). Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model. Cancer Res 60: 5456-5463.
Douglas JT, Kim M, Sumerel LA, Carey DE and Curiel DT (2001). Efficient oncolysis by a replicating adenovirus (Ad) in vivo is critically dependent on tumor expression of primary Ad receptors. Cancer Res 61: 813-817.
Barnett BG, Crews CJ and Douglas JT (2002). Targeted adenoviral vectors. Biochim Biophys Acta 1575: 1-14.
Barnett BG, Tillman BW, Curiel DT and Douglas JT (2002). Dual targeting of adenoviral vectors at the levels of transduction and transcription enhances the specificity of gene expression in cancer cells. Mol Ther 6: 377-385.
Douglas JT (2002). Targeted adenoviral vectors. Mol Phys 100: 3075-3091.
Kim M, Zinn KR, Barnett BG, Sumerel LA, Krasnykh V, Curiel DT and Douglas JT (2002). The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. Eur J Cancer 38: 1917-1926.

Biosketch

Current Positions

04/01 - present	Assistant Professor. University of Alabama at Birmingham, Departments of Medicine, Pathology and Surgery, Division of Human Gene Therapy.
12/97 - present	Associate Scientist. University of Alabama at Birmingham Comprehensive Cancer Center.
11/99 - present	Associate Scientist. University of Alabama at Birmingham Center for Metabolic Bone Disease.
7/00 - present	Associate Scientist. University of Alabama at Birmingham Gene Therapy Center.
02/02 - present	Associate Scientist. University of Alabama at Birmingham Arthritis and Musculoskeletal Diseases Center.

Academic Degrees

1987 University of Oxford B.A.

1991 University of Oxford M.A.

1995 University of Southampton Ph.D.